Evommune Doses First Patient in Phase 2b Migraine Trial
Evommune initiated a Phase 2b trial for EVO756 in migraine prophylaxis. This offering a new oral therapeutic option for patients not responding adequately to current treatments. The data is expected in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day